Clinical Trial Update: Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial of intracerebral IL-13-PE38QQR infusions in pediatric patients with recurrent malignant glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• IL-13-PE38QQR (Cintredekin besudotox) (Interleukin-13 fused to PE38QQR toxin)

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Recurrent Malignant Glioma | Phase 1, Phase 2 | Status: WITHDRAWN